BCG treatment refers to the medical use of Bacillus Calmette-Guérin, a live but weakened strain of bacteria related to the one that causes tuberculosis. It serves two very different purposes in medicine: as the world’s most widely used tuberculosis vaccine, given to infants in many countries, and as an immunotherapy instilled directly into the bladder to treat non-muscle-invasive bladder cancer. In the cancer setting, BCG remains the single most effective intravesical therapy available, capable of producing complete tumor regression in more than half of treated patients and, unlike standard chemotherapy, providing durable protection against recurrence lasting five years or more.
How BCG Works Against Bladder Cancer
BCG is not a chemotherapy drug. It does not poison cancer cells the way traditional cancer drugs do. Instead, it triggers a powerful immune response inside the bladder that ultimately teaches the body to attack the tumor itself. The process starts when the weakened bacteria are instilled through a catheter into the bladder, where they attach to and are internalized by both the bladder’s lining cells and the cancer cells themselves. Those cells then secrete signaling molecules that attract immune cells into the bladder wall.
The immune response that follows involves a broad cast of players. CD4 and CD8 lymphocytes, natural killer cells, granulocytes, macrophages, and dendritic cells all appear to contribute to the antitumor effect. Cancer cells that have taken up BCG essentially wave a flag for the immune system, presenting bacterial and tumor antigens that make them targets for destruction. This dual involvement of the tumor cells and the immune system is what makes BCG so effective as a cancer treatment, and it is part of why researchers have studied it as one of the earliest successful forms of cancer immunotherapy.1PubMed. The mechanism of action of BCG therapy for bladder cancer–a current perspective
Effectiveness Against Tumor Recurrence and Progression
For non-muscle-invasive bladder cancer, the main worry after surgery is that tumors come back. Standard intravesical chemotherapy reduces the short-term chance of recurrence by roughly 15 to 18 percent, but by five years out, patients who got chemotherapy and patients who got surgery alone tend to have similar recurrence rates. BCG does better. Controlled studies have found that BCG produces complete tumor regression in more than half of patients with papillary tumors and in over 70 percent of those with carcinoma in situ, and that protection against recurrence persists for five years or longer.2Urologic Clinics of North America. LONG-TERM RESULTS OF INTRAVESICAL THERAPY FOR SUPERFICIAL BLADDER CANCER
Beyond just keeping tumors from coming back, BCG also appears to slow disease progression. Three controlled studies have found statistically significant reductions in the rate at which non-muscle-invasive cancer advances to the muscle-invasive stage, and one found a significant drop in mortality. That progression-fighting ability is something intravesical chemotherapy has not been able to demonstrate convincingly.
A large patterns-of-care analysis using national cancer registry data reinforced how much BCG matters. Patients who received BCG had roughly half the hazard of recurrence compared to those who did not receive it, regardless of whether they were affected by periodic BCG supply shortages.3Urologic Oncology: Seminars and Original Investigations. THE IMPACT OF BCG SHORTAGE ON DISEASE RECURRENCE FOR PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: A SEER PATTERNS OF CARE ANALYSIS
The Standard Treatment Schedule
BCG treatment for bladder cancer is not a single shot. The standard protocol starts with an induction phase of six weekly instillations, where the BCG solution is placed into the bladder through a catheter and held for one to two hours. After induction, maintenance therapy follows, with the most common schedules involving additional instillations at three, six, and twelve months after the initial course. A widely used regimen calls for about 15 total instillations over the first year.
Getting the schedule right matters. A European phase III trial tested whether a reduced-frequency schedule of nine instillations could work as well as the standard 15. The trial was stopped early because the reduced schedule was clearly inferior: recurrence rates were more than double in the reduced-frequency arm. The researchers found that cutting back too aggressively on the number of instillations exposed patients to harm.4PubMed. Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations
On the other end, extending maintenance beyond one year does not seem to help. A systematic review and network meta-analysis found that three years of maintenance therapy was not superior to one year. What did matter was doing at least some maintenance rather than stopping after induction alone. Induction-only BCG performed worse, but extending therapy did not increase side effects significantly either.5PubMed. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer
There is also debate about whether to follow the classic SWOG protocol (clusters of three weekly instillations at set intervals) or a simpler monthly instillation approach. A comparative study found the two schedules produced similar five-year recurrence-free survival rates, around 65 to 71 percent, and similar progression-free survival around 89 to 91 percent. Both schedules also caused similar rates of patients dropping out because of side effects, roughly a quarter of patients in each group. Monthly maintenance appears to be a reasonable alternative when logistical considerations favor a simpler schedule.6PubMed. Comparison of Bacillus Calmette-Guérin Maintenance Therapy with Monthly Instillations and the Southwest Oncology Group Protocol in the Treatment of Non-muscle-invasive Bladder Cancer
Side Effects and Risks
Most people tolerate BCG reasonably well, but it is hardly a comfortable treatment. Bladder irritation, general malaise, and low-grade fever are extremely common, to the point that experiencing them is almost expected. About 8 percent of patients ultimately have to stop treatment because of complications.7PubMed Central. Managing the adverse events of intravesical bacillus Calmette-Guérin therapy
The rare but serious risk is systemic BCG infection, sometimes called BCG-osis or BCG sepsis. This happens when the live bacteria escape the bladder and spread through the body, causing high fever, septic shock, and potentially organ failure. The treatment is well tolerated in roughly 95 percent of cases, but the remaining fraction can face life-threatening complications.8PubMed Central. Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer A single-institution review put the incidence of severe systemic adverse events at about 1.5 percent. Of five patients in that series who developed severe complications, three died, underscoring that while the risk is small in percentage terms, it is not trivial when it occurs.9Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. Intravesical Bacillus Calmette-Guérin (BCG) treatment’s severe complications: A single institution review of incidence, presentation and treatment outcome
One complicating factor is that BCG infections can appear anywhere in the body and may show up weeks, months, or even years after treatment, making early diagnosis challenging. Treatment for severe cases involves antituberculosis drugs, typically a combination of isoniazid, rifampicin, and ethambutol, given for three to twelve months depending on severity. Corticosteroids are considered essential in BCG septicemia specifically.10PubMed Central. Managing the adverse events of intravesical bacillus Calmette-Guérin therapy
Do Different BCG Strains Matter?
BCG is not a single standardized product. Several genetically distinct strains are manufactured worldwide, including Tice, Connaught, RIVM, Tokyo 172, and others. Patients sometimes encounter different strains depending on what is available at their treatment center, which raises an obvious question: does the strain matter?
A network meta-analysis examining seven BCG strains across eleven studies found that RIVM, Tice, and Tokyo 172 showed the best predicted probability for efficacy, but no single strain was statistically superior to another in preventing recurrence.11PubMed Central. Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs) A head-to-head prospective trial comparing the Tokyo and Connaught strains found no significant differences in complete response rates, recurrence-free survival, or adverse event rates.12PubMed. A prospective comparative study of intravesical bacillus Calmette-Guérin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer
In practice, the strain you receive is largely a function of geography and supply rather than clinical choice. The evidence so far suggests this is acceptable, though researchers have noted that some strains may have subtle advantages worth investigating in future trials.
When BCG Stops Working
Not everyone responds to BCG, and some patients who initially respond eventually see their cancer return. The category of “BCG-unresponsive” disease is one of the most difficult problems in bladder cancer management. The standard recommendation when BCG fails is radical cystectomy, the surgical removal of the entire bladder, because effective salvage intravesical therapy has not been established. That recommendation puts urologists and patients in a tough spot: weighing the risk of cancer progression during further conservative treatment against the substantial morbidity of losing a bladder.13PubMed Central. Emerging intravesical therapies for the management of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer
Several newer therapies have emerged for this population. Pembrolizumab, a checkpoint inhibitor already widely used in other cancers, gained approval for BCG-unresponsive carcinoma in situ. A gene therapy called nadofaragene firadenovec has also entered the picture. But cost-effectiveness analyses have been sobering. One study found that pembrolizumab would need a price reduction of over 90 percent to become cost-effective compared to radical cystectomy.14PubMed. Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ of the Bladder A European analysis found that combination chemotherapy with gemcitabine and docetaxel and heated intravesical chemotherapy were far more cost-effective alternatives, with radical cystectomy itself remaining the cheapest option over a ten-year horizon.15PubMed. Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBC
BCG as a Tuberculosis Vaccine
Before BCG became a bladder cancer treatment, it was, and still is, primarily a vaccine against tuberculosis. It is the most widely administered vaccine in human history, given to newborns in most countries with high TB burden. Its record on safety over more than a century is remarkable. Its record on efficacy is more complicated.
A large individual-participant meta-analysis found that infant BCG vaccination provided meaningful protection against pulmonary tuberculosis, with an adjusted odds ratio of about 0.81, meaning roughly a 19 percent reduction in risk across participants. The protection was strongest in young children, with an adjusted odds ratio of 0.58 in children under three. However, BCG did not significantly protect against extrapulmonary tuberculosis at any age.16PubMed. Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course
The vaccine’s protection also appears to wane over time, which is one reason researchers have been trying to develop improved versions. A recent phase 3 trial tested VPM1002, a genetically modified BCG vaccine, against standard BCG in newborns. VPM1002 failed to meet non-inferiority criteria, with a hazard ratio of 1.23 compared to standard BCG, meaning the new vaccine actually trended toward less protection. Both vaccines had similar safety profiles.17PubMed. Comparison of VPM1002 with BCG in the prevention of tuberculosis in newborn infants Replacing BCG, it turns out, is harder than it looks.
Trained Immunity and the Broader Immune Effects of BCG
One of the most surprising discoveries about BCG in recent decades is that it does not just protect against tuberculosis. Vaccinated infants appear to have lower overall mortality than would be expected from TB prevention alone, suggesting that BCG somehow protects against a wider range of infections. This phenomenon is called trained immunity, and it has forced scientists to rethink some basic assumptions about how vaccines work.18PubMed Central. Heterologous effects of infant BCG vaccination: potential mechanisms of immunity
The classic view was that vaccines only train the adaptive immune system, the part that remembers specific pathogens. BCG does that too, but it also reprograms the innate immune system, the body’s fast-responding first line of defense that was long thought incapable of forming memories. A landmark study in healthy volunteers showed that BCG vaccination led to a two-fold increase in the production of key inflammatory molecules by monocytes when those monocytes were later exposed to completely unrelated bacteria and fungi. This enhanced innate response persisted for at least three months and was driven by chemical modifications to the DNA packaging inside those immune cells.19PubMed Central. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes
The mechanisms behind this include changes to gene accessibility and shifts in cellular metabolism, both of which are sustained by signals that reach all the way back to blood-forming stem cells in the bone marrow.20PubMed Central. BCG-induced trained immunity: history, mechanisms and potential applications Even more striking is the speed at which some of these effects kick in. Research has shown that within just three days of administration, BCG can reduce mortality from neonatal sepsis, likely through an emergency production of infection-fighting white blood cells.21PubMed Central. BCG vaccination-induced emergency granulopoiesis provides rapid protection from neonatal sepsis
BCG and Alzheimer’s Disease
The trained-immunity story has led researchers to look for other unexpected benefits of BCG, and the link to dementia is one of the most intriguing findings to emerge. Because bladder cancer patients treated with intravesical BCG receive repeated high-dose exposures, they form a natural population in which to study long-term effects.
Multiple observational studies have found that bladder cancer patients who received BCG treatment went on to develop Alzheimer’s disease and other forms of dementia at lower rates than similar patients who did not receive BCG. A U.S. study of over 6,400 bladder cancer patients found that BCG treatment was associated with a 20 percent lower risk of developing Alzheimer’s disease and related dementias, with the effect concentrated in patients aged 70 and older, where the risk reduction reached about 26 percent.22JAMA Network Open. Association of BCG Vaccine Treatment With Death and Dementia in Patients With Non–Muscle-Invasive Bladder Cancer A Swedish nationwide cohort study covering 1997 to 2019 found a similar protective association, with BCG-treated patients having roughly a 19 percent lower hazard of dementia compared to those who did not receive BCG.23PLoS ONE. The association between BCG treatment in patients with bladder cancer and subsequent risk of developing Alzheimer and other dementia
An earlier study reported an even more dramatic effect, with BCG-treated patients showing a highly significant reduction in Alzheimer’s risk compared to untreated bladder cancer patients.24PLOS ONE. Bacillus Calmette-Guérin (BCG) therapy lowers the incidence of Alzheimer’s disease in bladder cancer patients That study also checked for a link with Parkinson’s disease and found none, suggesting the association is not just a general “healthier patient” effect.
These are observational studies, not randomized trials, so they cannot prove causation. People who receive BCG for bladder cancer may differ from those who do not in ways that independently affect dementia risk. Still, the consistency of the finding across multiple countries and datasets, combined with what we know about BCG’s ability to reprogram immune cells, has made this a serious area of ongoing research rather than a statistical curiosity.
BCG in Multiple Sclerosis and Type 1 Diabetes
The immune-modulating properties of BCG have also drawn interest in autoimmune diseases. In multiple sclerosis, a small trial found that a single BCG vaccination reduced MRI-detectable brain lesion activity in patients, with no major adverse effects.25PubMed. Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis A longer-term study followed patients after their first demyelinating episode in the central nervous system and found that those who received BCG before starting disease-modifying therapy had roughly half the risk of progressing to clinically definite MS over five years compared to controls.26PubMed Central. Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS
In type 1 diabetes, a proof-of-concept trial in adults with long-standing disease found that BCG transiently modified the autoimmune process underlying the condition by stimulating the innate immune response. The researchers suggested that BCG or similar innate-immunity boosters could have value in treating long-term diabetes, though this remains an early-stage finding far from clinical practice.27PubMed Central. Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes
Both of these lines of research are still at the stage where the signal is interesting but the clinical implications remain uncertain. BCG is not a standard treatment for either MS or type 1 diabetes, and the trials have been small. What these findings do show is that BCG’s effects on the immune system are remarkably broad, reaching far beyond its original purpose.
Predicting Who Will Respond to BCG
One of the persistent frustrations with BCG therapy for bladder cancer is that there is no reliable way to know in advance which patients will benefit and which will not. If clinicians could identify non-responders early, those patients could be spared months of uncomfortable treatment and directed sooner toward surgery or alternative therapies.
Several candidate biomarkers have been identified over the years, including immune cell markers like CD68 and various genetic variations, but none has reached routine clinical use. Creating a reliable predictive profile likely requires combining multiple markers rather than relying on any single one.28PubMed Central. Predictive Biomarkers of Bacillus Calmette-Guérin Immunotherapy Response in Bladder Cancer: Where Are We Now?
More recently, researchers have turned to artificial intelligence. An AI-powered pathology tool, validated across twelve international centers, was able to identify patients at high risk of recurrence, progression, and the development of BCG-unresponsive disease by analyzing the tissue slides from tumor biopsies. Patients flagged as high-risk by the AI had roughly double the hazard of high-grade recurrence and nearly four times the hazard of progression compared to those classified as low-risk.29PubMed Central. Predicting Response to Intravesical Bacillus Calmette-Guérin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay
On the molecular side, the enzyme IDO1 has emerged as a particularly promising biomarker. Patients whose tumors expressed high levels of IDO1 were significantly more likely to fail BCG therapy, a finding confirmed at both the gene-expression and protein levels.30Cell Death Discovery. Heightened IDO1 levels predict Bacillus Calmette-Guèrin failure in high-risk non-muscle-invasive bladder cancer patients If validated in larger cohorts, IDO1 testing could eventually help guide the decision of whether to pursue BCG or go straight to more aggressive options.
Supply Shortages and the Cost of Alternatives
BCG has faced recurring global supply shortages since the early 2010s, driven by manufacturing difficulties and limited producers. Because BCG is a live biological product grown from bacterial cultures, scaling up production is not as simple as ramping up a pill factory. These shortages have forced clinics to ration doses, reduce maintenance schedules, or substitute alternative treatments.
The good news from the data is that patients who were affected by shortages but still managed to receive BCG had similar recurrence-free survival to patients treated during periods of normal supply. The problem was for patients who missed BCG entirely because of supply disruptions: their three-year recurrence-free survival dropped to roughly 47 percent compared to about 66 to 73 percent for those who received the treatment.31Urologic Oncology: Seminars and Original Investigations. THE IMPACT OF BCG SHORTAGE ON DISEASE RECURRENCE FOR PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: A SEER PATTERNS OF CARE ANALYSIS
When BCG is unavailable or has failed, the alternatives come with significant cost considerations. BCG itself is cheap as cancer treatments go. Radical cystectomy, the surgical standard for BCG-unresponsive disease, is expensive but durable. Newer agents like pembrolizumab are far more expensive. A European cost-effectiveness analysis found that over ten years, radical cystectomy cost roughly €22,000 per patient, gemcitabine-docetaxel chemotherapy about €48,000, and pembrolizumab over €200,000, while producing fewer quality-adjusted life years than some of the cheaper options.32PubMed. Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBC These figures put the BCG supply problem in perspective: the cheapest and most effective first-line treatment is also the one that is hardest to keep on pharmacy shelves, and the backups that exist are either life-altering surgery or prohibitively expensive drugs.